Labiotech.eu

News and Trends 28 Sep 2015

AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)

What was AbbVie thinking? Backing out of a $1.4Bn deal to support Belgian biotech Galapagos’ rheumatoid arthritis candidate through its phase III, means NASDAQ stock is plummeting in value since Friday. With plans to work on its own phase II candidate instead, AbbVie is losing out on the potential of filgotinib, which will surely have […]

September 28, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

Nestlé Institute of Health Sciences (NIHS) is teaming up with the Swiss AC Immune to develop a new minimally invasive Tau diagnostic assay for early diagnosis of Alzheimer’s disease. Alzheimer’s disease has a new case every three seconds, totaling up to 9.9 million new cases of dementia every year. To combat this, AC Immune will […]

September 28, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 27 Sep 2015

What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics

Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics Tuesday: the Francis Crick Institute announced its application to conduct new research on human embryos Wednesday: Israeli NovoCure announced an IPO on NASDAQ with a target of €170M Thursday: Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy […]

September 27, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 26 Sep 2015

Replimune smashes Oncolytic viral €26.8M series A financing round

Replimune is an Oxford (UK) biotech baby, having only been founded in April this year a spin-off of former US BioVex. Nonetheless, this hasn’t stopped its Series A finance round reaching up to €26.8M. Replimune’s focal research is in developing new immuno-oncology therapies using oncolytic viruses, inspired by BioVex-Amgen’s T-VEC success. Replimune was founded by […]

September 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Sep 2015

This week’s major stories outside the EU you NEED to read! (Martin Shkreli, Biolimb, OrbiMed)

Happy Saturday everyone! This week was full of so many good articles, we’re doing a top 7 top stories outside the EU you need to know! Yes, you heard correctly, seven of the best articles for your reading pleasure, you are most welcome ;). THE CEO WHO JACKED UP THE PRICE OF A DRUG BY 5000% […]

September 25, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 25 Sep 2015

Two French Biotechs are fighting in court…for nothing

We are all familiar with stories of lawsuits in the tech sector (e.g. remember the Apple and Samsung debacle?) but it’s less well known for Biotechs to butt heads. Nonetheless, the French-Danish Biotech oncology company Onxeo, and Eurofins (a huge 19K employee group which deals in clinical services) fought it out in Paris’ commerce court: to […]

September 25, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 25 Sep 2015

Roche’s patent halts an Amgen biosimilar debut

Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite smashing the phase III trials, the Amgen-Allergan partnership still has to wait until 2022 for Roche’s European Avastin patent to expire. Amgen partnered up with Dublin based Allergan (Ireland) for a comprehensive oncology biosimilars pipeline […]

September 25, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Sep 2015

Heart Attacks: TiGenix advances its cardiac stem-cell therapy

Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy at the Congress of the European Society of Cardiology (ESC) in London earlier this month. In July, TiGenix acquired the smaller biotech CoreTherapix with the AlloCSC-01 pipeline. This stem-cell therapy is for regeneration of heart muscle following a heart attack, and is currently […]

September 24, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 24 Sep 2015

Crowdsourcing for Innovation: BioMed X has just the right Recipe

Ever heard of BioMed X? If you are curious about innovation crowdsourcing, you should definitely check them out. BioMed X is one of the first companies to use crowdsourcing to discover new innovation in the life sciences, through which a biotech team has been assembled and financed to develop a new treatment for COPD. Chronic obstructive pulmonary […]

September 24, 2015 - 2 minutesmins - By Joachim Eeckhout

Inside Labiotech 23 Sep 2015

Labiotech.eu is 1 year old: Discover our Entrepreneurial Journey!

Hi there, Yesterday, with 30 guests from Berlin, we celebrated the first year of Labiotech.eu! Not only that we survived but we also have now more than 15,000 people visiting our website each month. Thank you all, that makes us the Europe’s leading digital media for Biotech! I am extremely proud of what we achieved and […]

September 23, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 23 Sep 2015

British Bionic Pancreas controlled by iPhone to revolutionize Type I Diabetes treatment

It’s finally happened; a research team from the University of Cambridge (UK) has managed to develop a closed loop beta-cell based insulin delivery system for diabetes type I. This bionic pancreas prototype has been constructed for human trials using an iPhone app which monitors blood glucose levels. There are 3 components to the bionic pancreas; […]

September 23, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 23 Sep 2015

NovoCure, the Israeli tumor specialist announces NASDAQ €170M IPO

NovoCure, originally from Haifa (Israel) is planning an IPO on NASDAQ with a target of €170M to make from its 12.5M shares on offer. It is hoped this financial injection will further commercialize its FDA-approved tumor treating field (TTField) medical device Optune. NovoCure is a commercial stage oncology biotech specialising in trials for solid-tumor treatments. Founded […]

September 23, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics

Replimune smashes Oncolytic viral €26.8M series A financing round

This week’s major stories outside the EU you NEED to read! (Martin Shkreli, Biolimb, OrbiMed)

Two French Biotechs are fighting in court…for nothing

Roche’s patent halts an Amgen biosimilar debut

Heart Attacks: TiGenix advances its cardiac stem-cell therapy

Crowdsourcing for Innovation: BioMed X has just the right Recipe

Labiotech.eu is 1 year old: Discover our Entrepreneurial Journey!

British Bionic Pancreas controlled by iPhone to revolutionize Type I Diabetes treatment

NovoCure, the Israeli tumor specialist announces NASDAQ €170M IPO

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!